According to relevant statistics, in December 2022, the total amount of holdings reduced by directors, supervisors and related persons of listed companies in Shanghai and Shenzhen was about 9.
375 billion yuan, involving 329 companies, and among the major industries, the pharmaceutical and biological industry reduced their holdings by 1.
819 billion yuan, involving 47 individual stocks, of which Cao Xiaochun, a director and executive of Tigermed Pharmaceutical, reduced his holdings by 477 million yuan in December, and included Aoxiang Pharmaceutical and Kanglong Chemical, etc
.
Entering 2023, there are still many pharmaceutical companies that have been reduced their
holdings.
On January 5, Lingrui Pharmaceutical issued a pre-disclosure announcement on the reduction of shares, and shareholders Wu Xizhen and Li Jin intend to reduce their holdings of the company's shares by no more than 248,100 shares from February 2, 2023 to August 1, 2023, and the reduction ratio will not exceed 0.
04%
of the company's total share capital.
According to the data, Lingrui Pharmaceutical's main business is the production and sales of drugs and health products, including proprietary Chinese medicines, chemicals, medical devices, and health products
.
News on January 4, Huahai Pharmaceutical was reduced by Shanghai Stock Connect by 2.
8317 million shares, with a new holding of 36.
4091 million shares, accounting for 2.
45%
of the total share capital of the company's A shares.
The company is mainly engaged in the research and development, production and sales of multi-dose generic drugs, biological drugs, innovative drugs and characteristic APIs, and is a large-scale pharmaceutical enterprise
integrating research, production and sales.
On January 4, Aoxiang Pharmaceutical was reduced by 112,200 shares by Shanghai Stock Connect, with a new holding of 1,683,400 shares, accounting for 0.
42%
of the total share capital of the company's A shares.
The company is mainly engaged in the research and development, production and sales of characteristic APIs and pharmaceutical intermediates, as well as providing customers with customized production and R & D business
.
On January 4, Jichuan Pharmaceutical was reduced by 931,500 shares by Shanghai Stock Connect, and the new holdings were 39,609,300 shares, accounting for 4.
30%
of the total share capital of the company's A shares.
Jichuan Pharmaceutical is mainly engaged in the research and development, production and sales
of drugs.
The company's drug product line mainly focuses on pediatrics, respiratory, digestion and other fields, the main products are Pudi blue anti-inflammatory oral liquid, pediatric soy clear heat granules, rabeprazole sodium enteric-coated capsules, etc
.
Senxuan Pharma announced on January 4 that its shareholder Tong Zhenming reduced his holdings by a total of 49,200 shares between November 25, 2022 and January 3, 2023, accounting for 0.
0116%
of the company's current total share capital.
It is reported that Senxuan Pharmaceutical is a chemical API manufacturer in the pharmaceutical manufacturing industry, and involves the production and sales of various API intermediates and pharmaceutical and chemical intermediates
.
Also on the 4th, Shanghai Pharmaceutical was reduced by 300,800 shares by Shanghai Stock Connect, and the new holding volume was 52,048,400 shares, accounting for 1.
87%
of the total share capital of the company's A shares.
Shanghai Pharmaceutical is a pharmaceutical group company with a whole industry chain layout, the company's main business covers the pharmaceutical industry, distribution and retail
.
On January 3, Yang Junwei, director of Dali Pharmaceutical, reduced his holdings of 4,900 shares of the company through secondary market trading, with an average transaction price of 13.
48 yuan per share, and a reduction of 66,100 yuan
.
According to the data, the main business of Dali Pharmaceutical is the production and sales
of Chinese and Western medicine injections.
On January 3, Wang Xuehai, director of Humanwell Pharmaceutical, reduced his holdings of 200,000 shares of the company through secondary market trading, with an average transaction price of 24.
0 yuan per share, reducing his holdings by 4.
8 million yuan
.
Renfu Pharmaceutical is mainly engaged in the research and development, production and sales
of drugs.
In addition, Zhaoyan New Drug issued an announcement on the evening of the 3rd that the company's shareholders Sun Huiye and Yin Lili completed the implementation of the reduction plan, reducing their holdings of about 18,600 shares of the company, accounting for 0.
0035% of
the company's total shares.
The main business of Zhaoyan New Drug is drug preclinical research services and the breeding and sales of laboratory animals, of which drug preclinical research services are the company's core business
.
.
.
.
.
.
.
The industry pointed out that the general shareholders to reduce their holdings after the big rise began to reduce their holdings, because some companies have obvious intrinsic value overvaluation, major shareholders will take advantage of the good market to reduce their holdings, but it should be noted that sometimes the majority shareholders may be behind the internal problems of the listed company, is the majority shareholders on the stock price reflection
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
